Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04504981 · ClinicalTrials.gov registry record · NA
Y2Prevent: Preventing Drug Use and HIV Through Empowerment, Social Support and Mentorship (Y2P)
A NA study of HIV and Drug Use, sponsored by Children's Hospital Los Angeles.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT04504981: Completed NA study of HIV and Drug Use, sponsored by Children's Hospital Los Angeles.
NCT04504981 is a NA study of HIV and Drug Use that has completed, run by Children's Hospital Los Angeles. The registered enrollment target is 27 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04504981, a NA study of HIV and Drug Use, has completed, sponsored by Children's Hospital Los Angeles.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to pilot test a group level intervention, called Y2Prevent, which aims to decrease drug use and HIV/STI risk among Black/African American young men who have sex with men (AAYMSM). The main question it aims to answer is: • determine if Y2Prevent is possible to engage in easily and is accepted by the participants, for potential expansion to other cities. Participants will engage in 7 weekly group sessions focused on helping AAYMSM identify life goals and safeguard their health to achieve those goals. This intervention will also include: * HIV/STI testing and treatment referral * drug screening and treatment referral * positive youth development and future planning through a mentorship program
Primary Outcome
Condomless anal intercourse; frequency of this behavior during reporting period; # of sexual partners during the reporting period; use of PrEP/PEP during reporting period
Interventions
- BEHAVIORAL Y2Prevent
Study Locations (1)
California
- Children's Hospital Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2020-01-22 |
| Est. Completion | 2023-03-01 |
| Phase | NA |
What the finished NCT04504981 record still lists
NCT04504981 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Y2Prevent is the first listed.
NCT04504981 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04504981 about?
NCT04504981 is a clinical study titled "Y2Prevent: Preventing Drug Use and HIV Through Empowerment, Social Support and Mentorship (Y2P)". The goal of this clinical trial is to pilot test a group level intervention, called Y2Prevent, which aims to decrease drug use and HIV/STI risk among Black/African American young men who have sex with men (AAYMSM). The main question it aims to answer is: • determine if Y2Prevent is possible to enga...
What is the current status of trial NCT04504981?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2020-01-22. Estimated completion is 2023-03-01.
What conditions does trial NCT04504981 study?
This clinical trial studies the following conditions: HIV, Drug Use.
What interventions are being tested in trial NCT04504981?
The interventions under investigation include: Y2Prevent (BEHAVIORAL).
Who is sponsoring clinical trial NCT04504981?
This trial is sponsored by Children's Hospital Los Angeles, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04504981 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04504981's enrollment target sits among peer trials
27 276th of 303 higher than 28 of 303 other HIV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
1MoreStep: An Intervention to Increase HIV Care Engagement and Reduce Intimate Partner Violence Among Black Women Living With HIV
RECRUITING · NA
-
Implementation Trial to Evaluate a Population Health Combination Intervention to Meet HIV Testing, Linkage, and Viral Suppression Goals in Alabama
RECRUITING · NA
-
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
RECRUITING · NA
-
Assessing Peer Support for Physical Activity in Women With HIV and Hypertension
RECRUITING · NA
-
Open Trial of Trauma-focused Psychodynamic Psychotherapy for People Living With HIV and PTSD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI